FDA Approves New Arthritis Drug

fdaFederal drug regulators have approved a new medicine for adults with moderate to severe rheumatoid arthritis who have not responded adequately to other treatments. The drug, which will be sold under the name Actemra, was developed by Roche’s subsidiary Genentech. The use of Actemra is limited to a specific group of patients because of serious safety issues observed in clinical studies. The problems observed in patients participating in clinical studies included elevated liver enzymes, hypertension, elevated cholesterol and gastrointestinal perforations.

The Food and Drug Administration is requiring Genentech to conduct a post-marketing clinical trial in order to evaluate Actemra’s long-term safety. Star Ledger.

This content, and any other content on TLS, may not be republished or reproduced without prior permission from TLS. Copying or reproducing our content is both against the law and against Halacha. To inquire about using our content, including videos or photos, email us at [email protected].

Stay up to date with our news alerts by following us on Twitter, Instagram and Facebook.

**Click here to join over 20,000 receiving our Whatsapp Status updates!**

**Click here to join the official TLS WhatsApp Community!**

Got a news tip? Email us at [email protected], Text 415-857-2667, or WhatsApp 609-661-8668.


Comments are closed.